Upgrade to SI Premium - Free Trial

Royalty Pharma (RPRX) PT Raised to $63 at BofA Securities

August 5, 2026 11:58 AM
BofA Securities analyst Jason Gerberry raised the price target on Royalty Pharma (NASDAQ: RPRX) to $63.00 (from $62.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change